[96a5a0]: / output / allTrials / identified / NCT00872482_identified.json

Download this file

593 lines (593 with data), 24.3 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
{
"info": {
"nct_id": "NCT00872482",
"official_title": "A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer",
"inclusion_criteria": "* Providing a written informed consent (see Appendix A);\n* Age ≥18 years;\n* Histologic or cytologic confirmed diagnosis of NSCLC of any epithelial type (squamous, adenocarcinoma, large cell, or other);\n* At least one newly diagnosed measurable metastatic lesion from NSCLC in the brain;\n* Patient had initial diagnosis of brain metastases by image, within 8 weeks of registration\n* KPS ≥70;\n* Absolute neutrophil count ≥ 1500/mm³;\n* Platelet count ≥ 50,000/mm³;\n* Serum creatinine ≤2.0 mg/dL;\n* Serum transaminases ≤2 x the upper limit of normal (ULN);\n* Total serum bilirubin ≤2 x ULN;\n* And a lactate dehydrogenase (LDH) level ≤1.3 x ULN.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Pregnancy, lactation or parturition within the previous 30 days (fertile female or male patients should practice contraception);\n* Prior WBRT, brain metastases resection with no other measurable lesion remaining;\n* Extracranial metastases in two or more organs;\n* Known leptomeningeal or subarachnoid tumor spread;\n* Plan to use radiosurgery or radiation boost after completion of WBRT;\n* Plan to use chemotherapy or any other systemic antineoplastic modality during WBRT;\n* Previous use of an anti-EGFR drug;\n* Participation in another ongoing therapeutic trial;\n* Presence of known HIV seropositivity, severe comorbidities, or other malignant neoplasm within 5 years (except adequately treated basal- or squamous-cell carcinoma of skin or in situ carcinoma of the uterine cervix);\n* Hypersensitivity or allergy to any of the drugs to be administered in this study;\n* Inability or unwillingness to complete the required assessments;\n* Geographic inaccessibility for treatment or follow-up evaluations.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Providing a written informed consent (see Appendix A);",
"criterions": [
{
"exact_snippets": "Providing a written informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "provision",
"expected_value": true
}
]
}
]
},
{
"line": "* Age ≥18 years;",
"criterions": [
{
"exact_snippets": "Age ≥18 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Histologic or cytologic confirmed diagnosis of NSCLC of any epithelial type (squamous, adenocarcinoma, large cell, or other);",
"criterions": [
{
"exact_snippets": "Histologic or cytologic confirmed diagnosis of NSCLC",
"criterion": "NSCLC diagnosis",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"histologic",
"cytologic"
]
}
]
},
{
"exact_snippets": "NSCLC of any epithelial type (squamous, adenocarcinoma, large cell, or other)",
"criterion": "NSCLC epithelial type",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"squamous",
"adenocarcinoma",
"large cell",
"other"
]
}
]
}
]
},
{
"line": "* At least one newly diagnosed measurable metastatic lesion from NSCLC in the brain;",
"criterions": [
{
"exact_snippets": "newly diagnosed measurable metastatic lesion from NSCLC in the brain",
"criterion": "metastatic lesion in the brain from NSCLC",
"requirements": [
{
"requirement_type": "diagnosis status",
"expected_value": "newly diagnosed"
},
{
"requirement_type": "measurability",
"expected_value": true
}
]
}
]
},
{
"line": "* Patient had initial diagnosis of brain metastases by image, within 8 weeks of registration",
"criterions": [
{
"exact_snippets": "initial diagnosis of brain metastases by image",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "diagnosis method",
"expected_value": "image"
}
]
},
{
"exact_snippets": "within 8 weeks of registration",
"criterion": "time since diagnosis",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 8,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* KPS ≥70;",
"criterions": [
{
"exact_snippets": "KPS ≥70",
"criterion": "Karnofsky Performance Status (KPS)",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": ">=",
"value": 70,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Absolute neutrophil count ≥ 1500/mm³;",
"criterions": [
{
"exact_snippets": "Absolute neutrophil count ≥ 1500/mm³",
"criterion": "absolute neutrophil count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* Platelet count ≥ 50,000/mm³;",
"criterions": [
{
"exact_snippets": "Platelet count ≥ 50,000/mm³",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 50000,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* Serum creatinine ≤2.0 mg/dL;",
"criterions": [
{
"exact_snippets": "Serum creatinine ≤2.0 mg/dL",
"criterion": "serum creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.0,
"unit": "mg/dL"
}
}
]
}
]
},
{
"line": "* Serum transaminases ≤2 x the upper limit of normal (ULN);",
"criterions": [
{
"exact_snippets": "Serum transaminases ≤2 x the upper limit of normal (ULN);",
"criterion": "serum transaminases",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "x ULN"
}
}
]
}
]
},
{
"line": "* Total serum bilirubin ≤2 x ULN;",
"criterions": [
{
"exact_snippets": "Total serum bilirubin ≤2 x ULN",
"criterion": "total serum bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "x ULN"
}
}
]
}
]
},
{
"line": "* And a lactate dehydrogenase (LDH) level ≤1.3 x ULN.",
"criterions": [
{
"exact_snippets": "lactate dehydrogenase (LDH) level ≤1.3 x ULN",
"criterion": "lactate dehydrogenase (LDH) level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.3,
"unit": "x ULN"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Pregnancy, lactation or parturition within the previous 30 days (fertile female or male patients should practice contraception);",
"criterions": [
{
"exact_snippets": "Pregnancy",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "lactation",
"criterion": "lactation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "parturition within the previous 30 days",
"criterion": "recent parturition",
"requirements": [
{
"requirement_type": "time since event",
"expected_value": {
"operator": "<=",
"value": 30,
"unit": "days"
}
}
]
},
{
"exact_snippets": "fertile female or male patients should practice contraception",
"criterion": "contraception",
"requirements": [
{
"requirement_type": "practice",
"expected_value": true
}
]
}
]
},
{
"line": "* Prior WBRT, brain metastases resection with no other measurable lesion remaining;",
"criterions": [
{
"exact_snippets": "Prior WBRT",
"criterion": "whole brain radiotherapy (WBRT)",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": true
}
]
},
{
"exact_snippets": "brain metastases resection",
"criterion": "brain metastases resection",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": true
}
]
},
{
"exact_snippets": "no other measurable lesion remaining",
"criterion": "measurable lesion",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Extracranial metastases in two or more organs;",
"criterions": [
{
"exact_snippets": "Extracranial metastases in two or more organs",
"criterion": "extracranial metastases",
"requirements": [
{
"requirement_type": "number of organs affected",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "organs"
}
}
]
}
]
},
{
"line": "* Known leptomeningeal or subarachnoid tumor spread;",
"criterions": [
{
"exact_snippets": "Known leptomeningeal ... tumor spread",
"criterion": "leptomeningeal tumor spread",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Known ... subarachnoid tumor spread",
"criterion": "subarachnoid tumor spread",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Plan to use radiosurgery or radiation boost after completion of WBRT;",
"criterions": [
{
"exact_snippets": "Plan to use radiosurgery",
"criterion": "radiosurgery",
"requirements": [
{
"requirement_type": "planned usage",
"expected_value": true
}
]
},
{
"exact_snippets": "radiation boost after completion of WBRT",
"criterion": "radiation boost",
"requirements": [
{
"requirement_type": "planned usage",
"expected_value": true
}
]
}
]
},
{
"line": "* Plan to use chemotherapy or any other systemic antineoplastic modality during WBRT;",
"criterions": [
{
"exact_snippets": "use chemotherapy or any other systemic antineoplastic modality during WBRT",
"criterion": "use of systemic antineoplastic modality during WBRT",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Previous use of an anti-EGFR drug;",
"criterions": [
{
"exact_snippets": "Previous use of an anti-EGFR drug",
"criterion": "anti-EGFR drug use",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Participation in another ongoing therapeutic trial;",
"criterions": [
{
"exact_snippets": "Participation in another ongoing therapeutic trial",
"criterion": "participation in another therapeutic trial",
"requirements": [
{
"requirement_type": "status",
"expected_value": "ongoing"
}
]
}
]
},
{
"line": "* Presence of known HIV seropositivity, severe comorbidities, or other malignant neoplasm within 5 years (except adequately treated basal- or squamous-cell carcinoma of skin or in situ carcinoma of the uterine cervix);",
"criterions": [
{
"exact_snippets": "Presence of known HIV seropositivity",
"criterion": "HIV seropositivity",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "severe comorbidities",
"criterion": "severe comorbidities",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "other malignant neoplasm within 5 years",
"criterion": "malignant neoplasm",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 5,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "* Hypersensitivity or allergy to any of the drugs to be administered in this study;",
"criterions": [
{
"exact_snippets": "Hypersensitivity or allergy to any of the drugs to be administered in this study",
"criterion": "hypersensitivity or allergy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Inability or unwillingness to complete the required assessments;",
"criterions": [
{
"exact_snippets": "Inability or unwillingness to complete the required assessments",
"criterion": "ability and willingness to complete assessments",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
},
{
"requirement_type": "willingness",
"expected_value": true
}
]
}
]
},
{
"line": "* Geographic inaccessibility for treatment or follow-up evaluations.",
"criterions": [
{
"exact_snippets": "Geographic inaccessibility for treatment or follow-up evaluations.",
"criterion": "geographic accessibility",
"requirements": [
{
"requirement_type": "accessibility",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}